Public Hearing
South Dakota Board of Certified Professional Midwives (CPM)
Thursday, April 21, 2022  1:30pm (Central Standard Time)

Steven Blair, Assistant Attorney General and Legal Counsel for the SD Board of CPM, called the public hearing to order at 1:30 p.m. on Thursday, April 21 2022 by telecommunication. He noted this hearing is being held at SD Board of CPM office at 27705 460th Ave. Chancellor SD and telephonically. Publication of this time and date has been set and published pursuant to SDCL 1-26-4 and SDCL 1-26-4.1. Members of the public were invited to join the Public Hearing at the SD Board of CPM Office or telephonically. Blair noted that this is the time and place for the Board of Certified Professional Midwives Public Hearing to consider changes to the administrative rules:

§ Chapter 20:86:02:03. Duration of license.
§ Chapter 20:86:04:02 Biennial renewal
§ Chapter 20:86:03 Appendix A THE FORMULARY
Adopted under the authority of SDCL 36-9C

Hearing Officer: Steven Blair, Assistant Attorney General and Legal Counsel for the SD Board of CPM
Rapid City

Members of the Board in attendance via teleconference: President Debbie Pease, Vice President Susan Rooks CNM, Kimberley McKay OB/GYN, and Jackie Lopez CPM. Secretary Autumn Cavender-Wilson CPM joined after the meeting was in progress.

In attendance in person: Board Executive Secretary Tammy Weis

Guests in attendance by telecommunication: Eudine Stevens CPM, Debbie Eakes CPM, Alaina Kerkhove CPM, Evie DeWitt Midwive’s Assistant and Doula, Justin Bell, Legal Counsel for South Dakota State Medical Association (SDSMA) and Dr. Keith Hanson OB/GYN speaking on behalf the of SDSMA, Bob Mercer, Keloland News.

Blair stated that those in attendance and statements made during the hearing were being recorded in the minutes and that a quorum of the board was present. Before beginning with any comments, and for the public record, he verified that the following information was in the CPM Board’s file for the record:

• Copy of proposed rules were submitted to Dept. of Health: 3/14/2022
• Sec. has given authorization to proceed: 3/14/2022
• Notice of Hearing prepared: 3/17/2022
• Notice publ. 3 papers gen. circulation
  o Rapid City Journal 3/19/2022
  o Brookings Register 3/21/2022
  o Aberdeen News 3/19/2022
• Affidavits of Publication from the papers received 4/1/2022
• Fiscal Note prepared by Tammy Weis 3/14/2022
• Small Business impact statement prepared 3/15/2022
The rules were presented by Tammy Weis Board Secretary. §Chapter 20:86:03 Appendix A and § Chapter 20:86:02:03, § Chapter 20:86:04:02.

Statute 36-9C-13 (SD Codified Laws, 2021) refers to prescription drugs that a licensed CPM may administer. These are as follows:

Vitamin K
Post-partum anti-hemorrhagic medication
Local anesthetic
IV antibiotics for treatment of Group B Strep
Oxygen
Eye prophylaxis
RhoGAM

This rule change would add IV fluid and Tranexamic Acid (TXA) to the Post-partum anti-hemorrhagic medication in an emergency situations. It will also include follow-up emergency treatment for allergic reactions that might arise from the use of the medications listed above. The final change will make the renewal of licenses more expedient, equitable, and in compliance with SDCL 36-9C-16.
The reason for adopting the proposed rules is to provide a greater protection for public safety.

Written Testimony:
Letter from SD Birth Matters, received April 15, 2022 —Proponent
  o Meghan Olson, Co-Chair, SD Birth Matters, Clear Lake, SD
  o Mandy Ulvestad, Co-Chair SD Birth Matters Pierre, SD
  o § Chapter 20:86:02:03. Duration of license. § Chapter 20:86:04:02 Biennial renewal and §Chapter 20:86:03 Appendix A THE FORMULARY
  o In favor and support of all proposed rule changes

Letter from Eudine Stevens CPM, Conde, SD- received April 18, 2022- Proponent
  o 20:86:03 Appendix A THE FORMULARY
  o Authorized use of IV antibiotics implies that a treatment for allergic reaction is also authorized.
  o TXA is recommended by World Health Organization regardless of the level of the health system resources

Letter from American College of Obstetricians and Gynecologists-received April 18, 2022- Opponent
  o Mark Ballard, MD Ob/Gyn, FACOG SD ACOG Section Chair
  o 20:86:03 Appendix A THE FORMULARY
  o Much of this 2 page letter is not germane to the rules hearing.
    - It cites IV fluids for hydration while we are discussing IV fluids as an emergency medication for postpartum hemorrhage.
FORM 10

- It discusses Epinephrine HCL for circulatory collapse while we are looking at a medication for severe allergic reactions to support the woman until she can be treated at a medical facility.
- It doesn’t cite a source or rationale why “We believe authorization for the use of this medication (Tranexamic Acid) is potentially dangerous.”
- The writer is obviously not familiar with the education and certificates held by all licensed SD midwives.
- It was difficult to find ways to address the comments or concerns because they were not on topic.

The board then heard public testimony from one opponent and five proponents.

Oral Testimony:

Opponent:
Dr Keith Hanson Ob/GYN from Sioux Falls, SD on behalf of the SDSMA, spoke first by prior arrangement. (Please note: the summary of Dr Hanson’s testimony has a few edits from the paper copy provided to legislators. His review and request for edits came after the paper copies were mailed. TW)

- Post-partum hemorrhage used to be a primary cause of maternal death but is now a rare occurrence because of good medical interventions now available
- Hemorrhage used to be one of the top 3 causes of postpartum morbidity and mortality.
- There are three primary causes of postpartum hemorrhage
  - Uterine atony
  - Retained placental tissue
  - Lacerations or trauma to cervical, vaginal or perineal tissues
  - Rare coagulopathies
- All three (four) would require expeditious transfer to the hospital for medical treatment
- Improvements in education, training, blood banking and medications have reduced morbidity and mortality from postpartum hemorrhage.
- Tranexamic Acid (TXA) side effects include blood clotting issues, which are life threatening must be addressed in a hospital setting
- IV side effects can include Pulmonary Edema from too much fluid too fast
- IV starts can be very difficult in hemorrhaging patients.
- Epinephrine HCL has a history of dosage mistakes (even) in the hospital setting.
- EpiPen® has a fixed dose

Primary Concerns of SDSMA
- Adding medication options may delay transfer to the hospital
- Dosage mistakes could be deadly
- Treatments for the noted side effects are unavailable outside of the hospital setting.

Proponents:
Eudine Stevens CPM from Conde, SD testified from Walla Walla, WA
- In rural areas it can take from 5-30 minutes for EMS to arrive.
- She has been present for over 200 out of hospital births and never had to use TXA but has worked with midwives who did have to use it.
- When bleeding is due to trauma, it can be very heavy with few direct pressure options
- 15 minutes while waiting for transfer can be life or death.
FORM 10

- Replacing fluid volume while waiting for transfer allows the hospital to receive the woman in better condition.

Alaina Kerkhove CPM from Colman, SD testified next
- She has lived in a rural South Dakota area for 27 years.
- Her local EMT is staffed by volunteers 25 miles away.
- They are EMT and not paramedics/ Many rural EMT crews cannot start IVs.
- The closest hospital that has the capacity to manage obstetrical emergencies is further away than the local hospital.
- Preloaded EpiPens® have no dosage risks for adults.

Evie DeWitt Midwife’s Assistant and Doula, Mitchell, SD
- Supports all four changes
- Agrees with all of the other proponent testimony
- Thanks the board for making birth safer for those who choose out of hospital birth

Debbie Eakes CPM- Montevideo, MN
- Thanked the board for taking up these issues for emergency situations
- Supports the changes and agrees with other proponent testimony

Blair closed the testimony period of the hearing at 1:55pm after hearing no more requests to testify.

The board began discussion and deliberation with the change in the renewal of licenses, § Chapter 20:86:02:03. Duration of license and § Chapter 20:86:04:02. Biennial renewal. LRC recommended corrections and changes were made. Pease suggested a change in the language to add “for” between “valid” and “two year” to clarify the beginning of the licensure period. Discussion: changing rule 20:86:02:03 made the first sentence in rule 20:86:04:02 unnecessary. Pease moved to adopt both rules as amended, Rooks Second. The voice vote was unanimous. Motion passed.

Final adopted rules:

20:86:02:03. Issuance of license. Licenses will be renewed biennially on October 30th.

Duration of license. A license is valid for two years from the date that it was issued by the board.

Source: 45 SDR 31, effective September 10, 2018.
General Authority: SDCL 36-9C-32(1).
Law Implemented: SDCL 36-9C-11, 36-9C-15

20:86:04:02. Biennial renewal. Each person licensed to practice within this state shall renew the license biennially on October 31st. The renewal fee is $1,500. Failure to secure a renewal certificate shall result in a lapsed license. A lapsed license may be reinstated as provided in § 20:86:02:06.

Source: 45 SDR 31, effective September 10, 2018.
General Authority: SDCL 36-9C-32(4).
Law Implemented: SDCL 36-9C-19(2).

FORMULARY CHANGE #1

Next the board discussed the expansion of the use of IV fluids from prophylactic antibiotic use only to use for postpartum hemorrhage as well. McKay addressed the concerns of the medical association, including the difficulty of IV starts when a woman is bleeding, and the possibility of delayed hospital transfer. The board was reminded that the initial concern that prompted the change to the rules was the question of:

1. If the CPM has the equipment to start an IV
2. If the CPM has the education and experience to start an IV
3. If the CPM doesn’t start an IV in the event of a postpartum hemorrhage because the rules do not specifically give authority to do so, will the CPM be considered negligent? (Especially in the case of an adverse event).
FORM 10

4. If the CPM does start and IV in the event of a postpartum hemorrhage and because the rules do not specifically give authority to do so, this action could be considered outside their scope of practice.

Discussion was active. All were in agreement that if Pitocin was not immediately effective, additional assessment and an early IV placement (earlier access is much easier) is the best safeguard to be prepared for a transfer if necessary. This is especially important in rural areas where EMTs may not have IV capacity and wait times for EMTs might be long. Final language was added to assure that hospital transfer was not delayed. The time that it takes to infuse the first liter (7-15 minutes) can be used for assessment and treatment. “With the start of the second liter, transport to hospital is required and local medical support will be notified.” This addresses the medical association’s concerns that transport be prioritized and ensures that the woman has replacement fluids during the transport process. LRC changes were previously made.

Cavender-Wilson moved to adopt the new rule as amended, Rooks second. The board voted with a unanimous voice vote. Motion passed

FORMULARY CHANGE #2
The next addition to the Formulary is Tranexamic Acid (TXA) for use for Postpartum Hemorrhage, to be used when initial anti-hemorrhagic therapies fail and with notification of local medical support. LRC corrections had been previously made. There was little discussion as it was more completely discussed at our previous meeting. Rooks moved to adopt the rule as written (after LRC changes) Cavender-Wilson second. The voice vote was unanimous. Motion passed

FORMULARY CHANGE #3
Epinephrine HCL is an important medication used for post-exposure treatment for severe allergic reactions. The board’s discussion of this medication centered around two issues

1. Epinephrine HCL has a terrible history of dosage mistakes by medical professionals. The dosages are weight dependent and a mistake is often deadly.
   a. The board addressed this issue by removing the dosage component and changed the request to use of an adult metered dose auto-injector also known as an EpiPen®
   b. The pen dosage is set at the pharmacy and cannot be changed.
   c. The board added “Maternal” to the indication because infant allergic reactions are extremely rare and will most likely not be needed.
2. The SDCL does not specifically name Epinephrine HCL.
   a. While it is not specifically named, “The ability for a health care provider to carry and to administer drugs of antibiotics, anti-hemorrhagic, or in the care for the newborn implies that they are also able to carry and administer the antidote in case of an allergic reaction…” Stevens CPM, written testimony.
   b. Severe allergic reactions to medications are rare but have become more prevalent.
   c. Many people at risk already carry an EpiPen®, but an allergic reaction can occur suddenly, requiring immediate response.
   d. The board is aware the LRC recommended that we remove this change but requested that the ARSD legislators consider public safety, the implied authority to carry the antidote to any medication that could potentially cause anaphylaxis and the safety of the EpiPen®.
The board will work toward changing the verbiage in the statute as soon as possible. For the interim, the board is requesting this addition to take place immediately in order to avoid the rare possibility of an adverse event, should rural EMS be too far away.

Final discussion was CPMs will “Seek medical support immediately after administration of first injection.” Activation of the EMS verbiage was rejected because sometimes it is faster to transport to the hospital via private vehicle.

**Rooks moved to adopt the rule as amended, McKay second.** The board voted by unanimous voice vote. **Motion carried**

Additions to the formulary

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
<th>Dose</th>
<th>Route of Administration</th>
<th>Duration of Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine HCL</td>
<td>Maternal post-exposure treatment for severe allergic reaction as follow-up to any approved medication</td>
<td>Adult metered dose auto-injector</td>
<td>Intramuscular injection into anterolateral aspect of the thigh via metered dose auto-injector</td>
<td>Seek medical support immediately after administration of first injection. May be given every 5-15 minutes as needed for up to 4 doses</td>
</tr>
<tr>
<td>Tranexamic Acid (TXA)</td>
<td>Postpartum Hemorrhage To be used when initial anti-hemorrhagic therapies fail and with notification of local medical support</td>
<td>100mg/ml (1 g)</td>
<td>IV at 1 ml per minute</td>
<td>2nd dose if bleeding continues past 30 min or restarts with 24 hours</td>
</tr>
<tr>
<td>IV Fluids</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Lactate Ringers (LR)</td>
<td></td>
<td>Infuse 1 liter at wide-open rate</td>
<td>IV line with 16-18 gauge needle</td>
<td>After first liter, a second liter may be titrated to client’s condition. With the start of the second liter, transport to hospital is required and local medical support will be notified.</td>
</tr>
<tr>
<td>- .45% Saline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- .9% Normal Saline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The board completed discussion, deliberation and voting to adopt the rules. There being no further business the public hearing was adjourned at 3:20.

Respectfully Submitted

Tammy Weis  Exec. Secretary